Update of Pharmacy Drug Coverage for Treatment of Obesity (GLP-1 receptor agonist medications)
Customize your policy alerts
Sign up for mclaren health plan Policy MSA 21-49 alerts
Get alerted when Policy MSA 21-49 changes without checking for updates manually.
Monitor payer policy activity
Updates Medicaid pharmacy coverage and prior authorization requirements for GLP-1 receptor agonist medications when prescribed solely for treatment of obesity; affects prescribers, pharmacies, and Medicaid beneficiaries covered under the referenced plan.
Coverage of GLP-1 medications prescribed solely to treat obesity will be reduced effective January 1, 2026.
Clinical PA criteria will require patients to be classified as morbidly obese and to have documented failure of all other clinically appropriate weight-loss interventions, and coverage should be considered to avert need for bariatric surgery.
Some GLP-1 medications (e.g., Saxenda and Wegovy) will become non-preferred on the Single Preferred Drug List starting January 1, 2026, affecting copayment amounts.
Coverage for GLP-1 medications for non-obesity indications will not change.
Coverage Criteria for GLP-1 Medications Prescribed Solely for Obesity
Clinical PA criteria for obesity-only GLP-1 coverage
Covered when ALL of the following are met:
From policy: patient must be classified as morbidly obese.
Coverage is contingent on documented failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred agents).
Policy specifies coverage must be considered only to avert bariatric surgery.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.